Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1

BACKGROUND: Improved lung function and fewer pulmonary exacerbations (PEx) were observed with lumacaftor/ivacaftor (LUM/IVA) in patients with cystic fibrosis homozygous for F508del. It is unknown whether PEx reduction extends to patients without early lung function improvement. METHODS: Post hoc ana...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cyst Fibros
Main Authors: McColley, Susanna A., Konstan, Michael W., Ramsey, Bonnie W., Elborn, J. Stuart, Boyle, Michael P., Wainwright, Claire E., Waltz, David, Vera-Llonch, Montserrat, Marigowda, Gautham, Jiang, John G., Rubin, Jaime L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6629021/
https://ncbi.nlm.nih.gov/pubmed/30146268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2018.07.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados